Indications for the drug Mexidol® solution for injection 5%
acute cerebrovascular accidents;
encephalopathy;
vegetative-vascular dystonia;
atherosclerotic disorders of brain function;
neurotic and neurosis-like disorders with anxiety;
relief of withdrawal syndrome in alcoholism with the presence in the clinical picture of neurosis-like and vegetative-vascular disorders, as well as acute intoxication with neuroleptics;
in the complex treatment of acute purulent-inflammatory processes of the abdominal cavity (acute destructive pancreatitis, peritonitis).
Mexidol amp 50mg/ml 2ml N10 (Vectorfarm)
IM or IV (stream or drip).
When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.
Mexidol® is injected slowly over 5-7 minutes in a stream, and dropwise at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.
For acute cerebrovascular accidents
Mexidol® is used in the first 10-14 days - 200-500 mg IV drip 2-4 times a day, then 200-250 mg IM 2-3 times a day for 2 weeks.
For traumatic brain injury and consequences of traumatic brain injury
Mexidol® is used for 10-15 days intravenously at a dose of 200-500 mg 2-4 times a day.
For dyscirculatory encephalopathy in the decompensation phase
Mexidol® should be prescribed intravenously in a stream or drip at a dose of 200-500 mg 1
-
2 times a day for 14 days. Then IM 100-250 mg/day. over the next 2 weeks.
For course prophylaxis of dyscirculatory encephalopathy
the drug is administered intramuscularly at a dose of 200-250 mg 2 times a day for 10-14 days.
For mild cognitive impairment in elderly patients and anxiety disorders
the drug is used intramuscularly at a daily dose of 100-300 mg/day for 14-30 days.
In acute myocardial infarction as part of complex therapy
Mexidol® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic agents according to indications.
In the first 5 days, to achieve maximum effect, it is advisable to administer the drug intravenously; in the next 9 days, Mexidol® can be administered intramuscularly. Intravenous administration of the drug is carried out by drip infusion, slowly (to avoid side effects) in a 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100-150 ml for 30-90 minutes. If necessary, a slow jet injection of the drug, lasting at least 5 minutes, is possible.
The drug is administered (intravenous or intramuscular) 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg/kg body weight per day, a single dose is 2-3 mg/kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.
For open-angle glaucoma of various stages as part of complex therapy
Mexidol® is administered intramuscularly at 100-300 mg/day, 1-3 times a day for 14 days.
For alcohol withdrawal syndrome
Mexidol® is administered in a dose of 200-500 mg intravenously or intramuscularly 2-3 times a day for 5-7 days.
In case of acute intoxication with antipsychotic drugs
the drug is administered intravenously at a dose of 200-500 mg/day for 7-14 days.
In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis)
the drug is prescribed on the first day both in the preoperative and postoperative periods. The administered doses depend on the form and severity of the disease, the prevalence of the process, and variants of the clinical course. The drug should be discontinued gradually only after a stable positive clinical and laboratory effect.
For acute edematous (interstitial) pancreatitis
Mexidol® is prescribed 200-500 mg 3 times a day, intravenously (in 0.9% sodium chloride solution) and intramuscularly.
Mild severity of necrotizing
pancreatitis
- 100-200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly.
Moderate severity
- 200 mg 3 times a day, intravenously (in 0.9% sodium chloride solution).
Severe course
— in a pulse dosage of 800 mg on the first day, with a two-time administration regimen; then 200-500 mg 2 times a day with a gradual reduction in the daily dose.
Extremely severe course
- at an initial dosage of 800 mg/day until the manifestations of pancreatogenic shock are persistently relieved, upon stabilization of the condition, 300-500 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.
Mexidol® (Mexidolum®)
IM or IV (stream or drip).
When administered by infusion, the drug should be diluted in 0.9% sodium chloride solution.
Mexidol® is injected slowly over 5-7 minutes in a stream, and dropwise at a rate of 40-60 drops per minute. The maximum daily dose should not exceed 1200 mg.
For acute cerebrovascular accidents
Mexidol® is used in the first 10-14 days - 200-500 mg IV drip 2-4 times a day, then 200-250 mg IM 2-3 times a day for 2 weeks.
For traumatic brain injury and consequences of traumatic brain injury
Mexidol® is used for 10-15 days intravenously at a dose of 200-500 mg 2-4 times a day.
For dyscirculatory encephalopathy in the decompensation phase
Mexidol® should be prescribed intravenously in a stream or drip at a dose of 200-500 mg 1
-
2 times a day for 14 days. Then IM 100-250 mg/day. over the next 2 weeks.
For course prophylaxis of dyscirculatory encephalopathy
the drug is administered intramuscularly at a dose of 200-250 mg 2 times a day for 10-14 days.
For mild cognitive impairment in elderly patients and anxiety disorders
the drug is used intramuscularly at a daily dose of 100-300 mg/day for 14-30 days.
In acute myocardial infarction as part of complex therapy
Mexidol® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic agents according to indications.
In the first 5 days, to achieve maximum effect, it is advisable to administer the drug intravenously; in the next 9 days, Mexidol® can be administered intramuscularly. Intravenous administration of the drug is carried out by drip infusion, slowly (to avoid side effects) in a 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100-150 ml for 30-90 minutes. If necessary, a slow jet injection of the drug, lasting at least 5 minutes, is possible.
The drug is administered (intravenous or intramuscular) 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg/kg body weight per day, a single dose is 2-3 mg/kg body weight. The maximum daily dose should not exceed 800 mg, single dose - 250 mg.
For open-angle glaucoma of various stages as part of complex therapy
Mexidol® is administered intramuscularly at 100-300 mg/day, 1-3 times a day for 14 days.
For alcohol withdrawal syndrome
Mexidol® is administered in a dose of 200-500 mg intravenously or intramuscularly 2-3 times a day for 5-7 days.
In case of acute intoxication with antipsychotic drugs
the drug is administered intravenously at a dose of 200-500 mg/day for 7-14 days.
In acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis)
the drug is prescribed on the first day both in the preoperative and postoperative periods. The administered doses depend on the form and severity of the disease, the prevalence of the process, and variants of the clinical course. The drug should be discontinued gradually only after a stable positive clinical and laboratory effect.
For acute edematous (interstitial) pancreatitis
Mexidol® is prescribed 200-500 mg 3 times a day, intravenously (in 0.9% sodium chloride solution) and intramuscularly.
Mild severity of necrotizing
pancreatitis
- 100-200 mg 3 times a day intravenously (in 0.9% sodium chloride solution) and intramuscularly.
Moderate severity
- 200 mg 3 times a day, intravenously (in 0.9% sodium chloride solution).
Severe course
— in a pulse dosage of 800 mg on the first day, with a two-time administration regimen; then 200-500 mg 2 times a day with a gradual reduction in the daily dose.
Extremely severe course
- at an initial dosage of 800 mg/day until the manifestations of pancreatogenic shock are persistently relieved, upon stabilization of the condition, 300-500 mg 2 times a day intravenously (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.
